Transgene SA (TNG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Transgene SA (TNG) has a cash flow conversion efficiency ratio of 5.046x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-18.18 Million ≈ $-21.26 Million USD) by net assets (€-3.60 Million ≈ $-4.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Transgene SA - Cash Flow Conversion Efficiency Trend (1997–2024)
This chart illustrates how Transgene SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TNG total debt and obligations for a breakdown of total debt and financial obligations.
Transgene SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Transgene SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Limoneira Co
NASDAQ:LMNR
|
0.005x |
|
LCNB Corporation
NASDAQ:LCNB
|
0.051x |
|
Acadian Timber Corp
TO:ADN
|
0.013x |
|
G1 Secure Solutions Ltd
TA:GOSS
|
0.143x |
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
-0.065x |
|
104 Corporation
TW:3130
|
0.097x |
|
Alro Slatina
RO:ALR
|
0.131x |
|
Kisco Holdings
KO:001940
|
0.014x |
Annual Cash Flow Conversion Efficiency for Transgene SA (1997–2024)
The table below shows the annual cash flow conversion efficiency of Transgene SA from 1997 to 2024. For the full company profile with market capitalisation and key ratios, see Transgene SA (TNG) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €15.20 Million ≈ $17.78 Million |
€-23.55 Million ≈ $-27.53 Million |
-1.549x | +30.26% |
| 2023-12-31 | €15.61 Million ≈ $18.25 Million |
€-34.67 Million ≈ $-40.53 Million |
-2.221x | -313.91% |
| 2022-12-31 | €37.84 Million ≈ $44.24 Million |
€-20.30 Million ≈ $-23.74 Million |
-0.537x | -12.89% |
| 2021-12-31 | €67.21 Million ≈ $78.57 Million |
€-31.94 Million ≈ $-37.34 Million |
-0.475x | +16.91% |
| 2020-12-31 | €50.25 Million ≈ $58.75 Million |
€-28.74 Million ≈ $-33.60 Million |
-0.572x | -67.66% |
| 2019-12-31 | €65.70 Million ≈ $76.81 Million |
€-22.41 Million ≈ $-26.20 Million |
-0.341x | +55.88% |
| 2018-12-31 | €36.70 Million ≈ $42.91 Million |
€-28.38 Million ≈ $-33.18 Million |
-0.773x | +38.59% |
| 2017-12-31 | €28.09 Million ≈ $32.84 Million |
€-35.37 Million ≈ $-41.35 Million |
-1.259x | -74.35% |
| 2016-12-31 | €46.50 Million ≈ $54.37 Million |
€-33.59 Million ≈ $-39.26 Million |
-0.722x | +57.54% |
| 2015-12-31 | €26.55 Million ≈ $31.04 Million |
€-45.15 Million ≈ $-52.79 Million |
-1.701x | -125.29% |
| 2014-12-31 | €71.84 Million ≈ $83.99 Million |
€-54.24 Million ≈ $-63.41 Million |
-0.755x | +14.82% |
| 2013-12-31 | €56.62 Million ≈ $66.20 Million |
€-50.19 Million ≈ $-58.67 Million |
-0.886x | -72.06% |
| 2012-12-31 | €99.58 Million ≈ $116.42 Million |
€-51.29 Million ≈ $-59.97 Million |
-0.515x | -64.95% |
| 2011-12-31 | €141.42 Million ≈ $165.33 Million |
€-44.16 Million ≈ $-51.63 Million |
-0.312x | -130.02% |
| 2010-12-31 | €183.62 Million ≈ $214.67 Million |
€-24.93 Million ≈ $-29.14 Million |
-0.136x | +50.28% |
| 2009-12-31 | €68.56 Million ≈ $80.16 Million |
€-18.72 Million ≈ $-21.89 Million |
-0.273x | -10.00% |
| 2008-12-31 | €94.22 Million ≈ $110.16 Million |
€-23.39 Million ≈ $-27.34 Million |
-0.248x | -1228.28% |
| 2007-12-31 | €110.94 Million ≈ $129.70 Million |
€-2.07 Million ≈ $-2.42 Million |
-0.019x | +98.18% |
| 2006-12-31 | €18.98 Million ≈ $22.19 Million |
€-19.54 Million ≈ $-22.84 Million |
-1.029x | +23.32% |
| 2004-12-31 | €14.23 Million ≈ $16.64 Million |
€-19.11 Million ≈ $-22.34 Million |
-1.343x | -154.45% |
| 2003-12-31 | €34.52 Million ≈ $40.36 Million |
€-18.21 Million ≈ $-21.29 Million |
-0.528x | -81.78% |
| 2002-12-31 | €55.21 Million ≈ $64.54 Million |
€-16.02 Million ≈ $-18.73 Million |
-0.290x | -35.93% |
| 2001-12-31 | €73.63 Million ≈ $86.08 Million |
€-15.72 Million ≈ $-18.38 Million |
-0.214x | +66.64% |
| 2000-12-31 | €34.79 Million ≈ $40.67 Million |
€-22.27 Million ≈ $-26.03 Million |
-0.640x | -155.78% |
| 1999-12-31 | €55.48 Million ≈ $64.86 Million |
€-13.88 Million ≈ $-16.23 Million |
-0.250x | +45.04% |
| 1998-12-31 | €73.49 Million ≈ $85.92 Million |
€-33.47 Million ≈ $-39.13 Million |
-0.455x | +19.95% |
| 1997-12-31 | €20.68 Million ≈ $24.18 Million |
€-11.77 Million ≈ $-13.76 Million |
-0.569x | -- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more